Costs and Cost-Effectiveness of Plasmodium vivax Control
| Autor: | Shunmay Yeung, Edith Patouillard, Michael T. White, Richard E Cibulskis |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Mosquito Control Primaquine Cost effectiveness Cost-Benefit Analysis 030231 tropical medicine Plasmodium vivax Psychological intervention Biology Antimalarials 03 medical and health sciences 0302 clinical medicine Virology parasitic diseases Malaria Vivax medicine Animals Humans 030212 general & internal medicine Intensive care medicine health care economics and organizations Articles medicine.disease biology.organism_classification Culicidae Infectious Diseases Immunology Parasitology Malaria medicine.drug |
| Zdroj: | The American Journal of Tropical Medicine and Hygiene |
| ISSN: | 1476-1645 0002-9637 |
| DOI: | 10.4269/ajtmh.16-0182 |
| Popis: | The continued success of efforts to reduce the global malaria burden will require sustained funding for interventions specifically targeting Plasmodium vivax. The optimal use of limited financial resources necessitates cost and cost-effectiveness analyses of strategies for diagnosing and treating P. vivax and vector control tools. Herein, we review the existing published evidence on the costs and cost-effectiveness of interventions for controlling P. vivax, identifying nine studies focused on diagnosis and treatment and seven studies focused on vector control. Although many of the results from the much more extensive P. falciparum literature can be applied to P. vivax, it is not always possible to extrapolate results from P. falciparum–specific cost-effectiveness analyses. Notably, there is a need for additional studies to evaluate the potential cost-effectiveness of radical cure with primaquine for the prevention of P. vivax relapses with glucose-6-phosphate dehydrogenase testing. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|